Patent ID: 8288087

Claim:
A method for determining a response of a mammalian subject having human melanoma tumor cells to treatment with CHIR-265, comprising: (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample comprising plasma, taken from the mammalian subject prior to initiation of treatment with CHIR-265; (b) selecting the mammalian subject having a first concentration of MIA of at least 16 ng/mL for treatment with CHIR-265; (c) determining a second concentration of MIA in a second biological sample comprising plasma, taken from the mammalian subject after initiation of treatment with CHIR-265; and (d) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with CHIR-265.